Xanthotoxol
Based on 2 publication(s) in Google Scholar
Xanthotoxol (8-Hydroxypsoralen) It is a kind of fragrant bean substance, and it is a CYP450 inhibitor. Xanthotoxol has anti-inflammatory, anti-inflammatory, and 5-HT antagonistic and protective effects. Xanthotoxol inhibited CYP3A4 sum CYP1A2 IC50s separation 7.43 μM sum 27.82 μM. Xanthotoxol can pass through MAPK and NF-κB, inhibiting inflammation.
For research use only. We do not sell to patients.
- Purity: 99.46%
- CAS No.: 2009-24-7
- Formula: C11H6O4
- Molecular Weight:202.16
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Xanthotoxol
MoreAll 5-HT Receptor Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
serotonin |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | IC50 |
>500 μM
Compound: 10
|
Anticorpulence activity against mouse 3T3L1 cells assessed as inhibition of lipid droplet accumulation
Anticorpulence activity against mouse 3T3L1 cells assessed as inhibition of lipid droplet accumulation
|
[PMID: 19054677] |
| HT-29 | IC50 |
>500 μM
Compound: 10
|
Anticancer activity against human HT-29 cells after 72 hrs by MTT assay
Anticancer activity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 19054677] |
Xanthotoxol (62.5-250 μM; 20 min) reduces the production of inflammatory factors induced by LPS stimulation in a concentration-dependent manner and inhibits LPS-induced p65 translocation from the cytoplasm to the nucleus in RAW 264.7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2009-24-7
-
Appearance Solid
-
Molecular Weight 202.16
-
Formula C11H6O4
-
Color Off-white to light yellow
-
SMILES
O=C1OC(C(C=C1)=C2)=C(O)C3=C2C=CO3
-
Synonyms
8-Hydroxypsoralen
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Eur J Pharmacol
2023 Dec 5:960:176147. PMID: 37871763 -
Solvent & Solubility
DMSO : 100 mg/mL (494.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ma Z, et al. Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509. [Content Brief]
[2]. Ma Z, et al. Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509. [Content Brief]
[3]. He W, et al. Xanthotoxol exerts neuroprotective effects via suppression of the inflammatory response in a rat model of focal cerebral ischemia. Cell Mol Neurobiol. 2013 Jul;33(5):715-22. [Content Brief]
[4]. Lee Y, et al. Anti-Inflammatory Effects of Psoralen Derivatives on RAW264.7 Cells via Regulation of the NF-κB and MAPK Signaling Pathways. Int J Mol Sci. 2022 May 22;23(10):5813. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.9466 mL | 24.7329 mL | 49.4658 mL | 123.6644 mL |
| 5 mM | 0.9893 mL | 4.9466 mL | 9.8932 mL | 24.7329 mL | |
| 10 mM | 0.4947 mL | 2.4733 mL | 4.9466 mL | 12.3664 mL | |
| 15 mM | 0.3298 mL | 1.6489 mL | 3.2977 mL | 8.2443 mL | |
| 20 mM | 0.2473 mL | 1.2366 mL | 2.4733 mL | 6.1832 mL | |
| 25 mM | 0.1979 mL | 0.9893 mL | 1.9786 mL | 4.9466 mL | |
| 30 mM | 0.1649 mL | 0.8244 mL | 1.6489 mL | 4.1221 mL | |
| 40 mM | 0.1237 mL | 0.6183 mL | 1.2366 mL | 3.0916 mL | |
| 50 mM | 0.0989 mL | 0.4947 mL | 0.9893 mL | 2.4733 mL | |
| 60 mM | 0.0824 mL | 0.4122 mL | 0.8244 mL | 2.0611 mL | |
| 80 mM | 0.0618 mL | 0.3092 mL | 0.6183 mL | 1.5458 mL | |
| 100 mM | 0.0495 mL | 0.2473 mL | 0.4947 mL | 1.2366 mL |